On the hunt for undruggable targets, Vividion Therapeutics has entered into a collaboration with Tavros Therapeutics to identify four cancer targets, with an option to pursue up to five more. The alliance, worth up to US$930 M, will combine Tavros’ precision oncology platform with Vividion’s ability to identify previously ‘undruggable’ binding pockets on oncology targets of high interest. The deal comes just over a year after Bayer acquired Vividion for US$2 B, as it looks to bolster its pipeline and prepare for the patent expiries of leading drugs, Eylea® (aflibercept) and Xarelto® (rivaroxaban).